Immunotherapy plus chemotherapy before and after surgery for pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery helps shrink tumors and improve outcomes for people with pancreatic cancer that can be removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have pancreatic cancer that is confirmed by biopsy and is removable with surgery (or borderline removable).
- You must not have had any prior treatment for this cancer, like chemotherapy, radiation, or other therapies.
- Your overall health must be good enough (able to care for yourself) and your blood counts and organ function must be within normal ranges.
- You cannot have other active cancers, serious infections, or heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two drugs for advanced pancreatic cancer. It aims to see if adding an immunotherapy drug (which helps your immune system attack cancer) to standard chemotherapy can help control the cancer better.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery for pancreatic cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial combines the immunotherapy drug sintilimab with chemotherapy and radiation for people with inoperable locally advanced pancreatic cancer who have not received prior systemic treatment. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests a combination of a chemotherapy drug (irinotecan liposome) plus an immunotherapy drug (addebelizumab) given before surgery to people with pancreatic cancer that can be fully removed. The goal is to see if this treatment reduces the chance of the cancer coming back and improves outcomes.
Hear when a new Pancreatic Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.